Strides Shasun gets USFDA approval for Cyproheptadine Hydrochloride Tablets
Strides Shasun gets USFDA approval for Cyproheptadine Hydrochloride Tablets

Strides Shasun gets USFDA approval for Cyproheptadine Hydrochloride Tablets

Nidhi Jani Article rating: 5.0

Strides Shasun’s wholly-owned subsidiary Strides Pharma Global Pte. Ltd. has received approval for Cyproheptadine Hydrochloride Tablets from the United States Food & Drug Administration (USFDA), keeping its ANDA approval momentum intact.

Ten stocks close to their 52-week high
Ten stocks close to their 52-week high

Ten stocks close to their 52-week high

Shital Jibhe Article rating: 5.0

The markets on April 12, 2018 opened up. BSE Sensex is trading at 34,034.90, up by 94.46 points and the Nifty is trading at 10,431.75, up by 14.60 points.

Mutual fund Unlocked: Debt mutual fund categories
Mutual fund Unlocked: Debt mutual fund categories

Mutual fund Unlocked: Debt mutual fund categories

Nikhil Desai Article rating: 5.0

Market regulator SEBI (Securities and Exchange Board of India) has directed fund houses to re-categories the universe of their offerings in distinct and new categories specified by the SEBI. Under debt funds category, there are 16 sub categories under which the fund houses need to realign their existing schemes

Five stocks with selling interest
Five stocks with selling interest

Five stocks with selling interest

Shital Jibhe Article rating: 5.0

Overall volumes in futures & options currently stand at 80.53 lakh contracts with a turnover of Rs. 7,34,207.42 crore.

Five stocks with buying interest
Five stocks with buying interest

Five stocks with buying interest

Shital Jibhe Article rating: 5.0

Overall volumes in futures & options currently stand at 80.53 lakh contracts with a turnover of Rs. 7,34,207.42 crore.

RSS
First35213522352335243526352835293530Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR